The biotech is starting up with partial rights to a drug that’s approved in multiple Asian countries and its executives see ...

Star hopes its drug, which is currently in late-stage testing, might prove a more convenient, longer-lasting alternative to ...

The deal hands Genmab a drug that showed the potential in earlier testing to extend survival in head and neck cancer when ...

Walmsley, who helped push GSK to focus more exclusively on specialty medicines and oncology, will be succeeded by commercial ...

Anticipated late-stage results in the skin disease hidradenitis suppurativa were described by analysts as “disappointing” and ...

Learn how softgels have helped sponsors across the industry improve the efficacy and stability of their therapeutics.

Carve-outs for generics, European exports and companies onshoring drug production will likely shield most branded drugs from ...

Crinetics’ acromegaly treatment will go up against several entrenched medicines. Elsewhere, Bristol Myers moved to sell Sotyktu online at a discount and regulators rejected a new version of Biogen’s ...

The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable ...

Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in ...

Two months after its treatment for Duchenne-related cardiomyopathy was rejected, the company aligned with the agency on a ...

Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...